Imaging DIagnostic and Treatment Of Prostate cancer

IDITOP est accrédité par Lyonbiopôle

Identity card

Global budget: 4838 k€

Public funding: 2385 k€

Public funders: FEDER Rhône-Alpes, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Région Rhône-Alpes, Other (Conseil Régional PACA)

Call for projects: FUI (FUI AAP12)

Year start: 2011

Completed project (2014-08)

Accredited by the French competitiveness cluster Lyonbiopôle

Co-accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Medical Technologies

Application fields: Oncology

Technological approaches / Keywords: Imaging (medical), Minimally Invasive Technologies, Radiotherapy

Stage of development at the beginning of the project:


The project aims at developing a new medical device to treat localized prostate cancer. This system will integrate innovative imaging and focused ultrasound treatment modalities developed by the three partners. It will allow for an efficient, non-invasive and costless therapeutic approach of the prostate cancer by offering patients and physicians a focal treatment. This focal approach aims at precisely controlling the cancer by limiting the treatment to tumor areas only. The focal treatment is to become the new therapeutic option for early diagnosed localized prostate cancer.


Thanks to IDITOP, all three partners will be able to put together their expertise and their know-how in innovative imaging (SSI) and therapeutic (EDAP TMS) technologies, and their clinical experience (HCL). They will contribute to the success of IDITOP project by concurring in developing a new prostate cancer non-invasive treatment: the « focal-HIFU » approach. 

Innovative assets
Actual results

Innovative assets

IDITOP allows for innovative: - MRI import and fusion of prostate images with real-time ultrasound images, - Precise contour definition of targeted tumor areas, - Non-invasive dynamic focusing HIFU delivery, - Immediate validation of treated areas using contrast imaging.